DiscoveryBioMed Awarded Phase 1 SBIR Catalyst Grant under The Recovery Act by the National Institutes of Health (NIH) to Discover Anti-Inflammatory Drugs

BIRMINGHAM, Ala.--(BUSINESS WIRE)--DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $200,000 Small Business Innovations Research (SBIR) Phase 1 grant by the National Institutes of Health (NIH) to continue research into the discovery and development of anti-inflammatory phytochemicals to address complications associated with nasal and pulmonary inflammation, dermatitis, and kidney disorders with an inflammatory component. DiscoveryBioMed, Inc. (DBM) will be working with ChromaDex Corp. (OTCBB: CDXC), who will be providing a library of natural products and phytochemicals to screen in their human cell platform.